NCT05364073
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
- NCT05364073 ↗
- Active, not recruiting
- ArriVent BioPharma, Inc.
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT05364073 (furmonertinib in advanced or metastatic NSCLC with EGFR/HER2 mutations) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05364073 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer (NSCLC); Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer; HER2 Exon 20 Mutations; EGFR Exon 20 Mutations; EGFR Uncommon Mutations, Including G719X and S768I
- Interventions
- Furmonertinib; Furmonertinib; Furmonertinib; Furmonertinib; Furmonertinib
- Arms
- Stage 1 Dose Escalation and Backfill · Experimental
- Stage 2 Expansion Cohort 1 · Experimental
- Stage 2 Expansion Cohort 2 · Experimental
- Stage 2 Expansion Cohort 3 · Experimental
- Stage 2 Expansion Cohort 4 · Experimental
- Enrollment
- 160
- Primary outcomes
- Stage 1: Number of incidence and severity of adverse events (AEs) as a measure of safety and tolerability of Furmonertinib
- Stage 2: Overall Response Rate (ORR)
- Sponsor
- ArriVent BioPharma, Inc.
- Start
- Jun 30, 2022
- Primary completion
- Jun 3, 2025
- Results posted
- No
- Registry record
- NCT05364073 · updated Mar 13, 2026